Price Alert

Viridian Therapeutics Inc... (VRDN)

NASDAQ: VRDN · Real-Time Price · USD

18.53

0.09 (0.49%)

At close: Aug 15, 2025, 3:59 PM

18.54

0.05%

After-hours: Aug 15, 2025, 05:32 PM EDT

0.49% (1D)

Bid	16
Market Cap	1.51B
Revenue (ttm)	305K
Net Income (ttm)	-344.06M
EPS (ttm)	-3.57
PE Ratio (ttm)	-5.19
Forward PE	-4.2
Analyst	Buy

Ask	19.1
Volume	743,746
Avg. Volume (20D)	749,275
Open	18.47
Previous Close	18.44
Day's Range	17.67 - 18.56
52-Week Range	9.90 - 27.20
Beta	0.48

About VRDN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VRDN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Viridian Therapeutics has released their quartely earnings on Aug 6, 2025:

Revenue of $75K misses estimates by $13.2K, with 4.17% YoY growth.

EPS of -1 misses estimates by -0.02, with 1.96% YoY growth.

Next Earnings Release

Viridian Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+6.02%

Viridian Therapeutics shares are trading higher af... Unlock content with Pro Subscription

2 months ago

+7.8%

Viridian Therapeutics shares are trading higher after the company announced positive long-term durability data from its THRIVE Phase 3 clinical trial of veligrotug in TED patients.

News

1 week ago · benzinga.com

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.

1 week ago · fool.com

Viridian (VRDN) Q2 Net Loss Widens 55%

1 week ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago.

1 week ago · businesswire.com

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...

1 week ago · businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains...